184 related articles for article (PubMed ID: 34036002)
1. A Case of Muir-Torre Syndrome.
Sheth R; Menon P; Malik D
Cureus; 2021 Apr; 13(4):e14582. PubMed ID: 34036002
[TBL] [Abstract][Full Text] [Related]
2. Germline Testing of Mismatch Repair Genes Is Needed in the Initial Evaluation of Patients With Muir-Torre Syndrome-Associated Cutaneous Sebaceous Neoplasms: A Case Series.
Cohen PR; Kurzrock R
Cureus; 2023 Jan; 15(1):e33975. PubMed ID: 36824550
[TBL] [Abstract][Full Text] [Related]
3. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
Ponti G; Manfredini M; Tomasi A; Pellacani G
Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
[TBL] [Abstract][Full Text] [Related]
4. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.
Ponti G; Losi L; Pedroni M; Lucci-Cordisco E; Di Gregorio C; Pellacani G; Seidenari S
J Invest Dermatol; 2006 Oct; 126(10):2302-7. PubMed ID: 16826164
[TBL] [Abstract][Full Text] [Related]
5. Case Report: A Frameshift Mutation in MSH2 Exon 2 in a Kidney Recipient With Muir-Torre Syndrome.
Feng Y; Feng J; Bao J
Front Oncol; 2021; 11():681780. PubMed ID: 34249727
[TBL] [Abstract][Full Text] [Related]
6. A case report of Muir-Torre syndrome in a woman with breast cancer and MSI-Low skin squamous cell carcinoma.
Kientz C; Joly MO; Faivre L; Clemenson A; Dalac S; Lepage C; Chapusot C; Jacquot C; Schiappa R; Lebrun M
Hered Cancer Clin Pract; 2017; 15():6. PubMed ID: 28507641
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Molecular Features of Skin Malignancies in Muir-Torre Syndrome.
Simic D; Dummer R; Freiberger SN; Ramelyte E; Barysch MJ
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065301
[TBL] [Abstract][Full Text] [Related]
8. Somatic MMR gene mutations as a cause for MSI-H sebaceous neoplasms in Muir-Torre syndrome-like patients.
Joly MO; Attignon V; Saurin JC; Desseigne F; Leroux D; Martin-Denavit T; Giraud S; Bonnet-Dupeyron MN; Faivre L; Auclair J; Grand-Masson C; Audoynaud C; Wang Q
Hum Mutat; 2015 Mar; 36(3):292-5. PubMed ID: 25504677
[TBL] [Abstract][Full Text] [Related]
9. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test.
Mathiak M; Rütten A; Mangold E; Fischer HP; Ruzicka T; Friedl W; Propping P; Kruse R
Am J Surg Pathol; 2002 Mar; 26(3):338-43. PubMed ID: 11859205
[TBL] [Abstract][Full Text] [Related]
10. Muir-Torre syndrome in a haemodialysis patient.
Godfrey ED; Coward RA; Gharpuray-Pandit D; Lalloo F; McKirdy S; Woywodt A
Clin Kidney J; 2013 Aug; 6(4):414-7. PubMed ID: 27293570
[TBL] [Abstract][Full Text] [Related]
11. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry.
Ponti G; Losi L; Di Gregorio C; Roncucci L; Pedroni M; Scarselli A; Benatti P; Seidenari S; Pellacani G; Lembo L; Rossi G; Marino M; Lucci-Cordisco E; Ponz de Leon M
Cancer; 2005 Mar; 103(5):1018-25. PubMed ID: 15662714
[TBL] [Abstract][Full Text] [Related]
12. Muir-Torre syndrome and recent updates on screening guidelines: The link between colorectal tumors and sebaceous adenomas in unusual locations.
Shaker N; Shaker N; Abid A; Shah S; Shakra RA; Sangueza OP
J Surg Oncol; 2023 Dec; 128(8):1380-1384. PubMed ID: 37706607
[TBL] [Abstract][Full Text] [Related]
13. Muir-Torre syndrome-associated pleomorphic liposarcoma arising in a previous radiation field.
Yozu M; Symmans P; Dray M; Griffin J; Han C; Ng D; Parry S; Wong K
Virchows Arch; 2013 Mar; 462(3):355-60. PubMed ID: 23299928
[TBL] [Abstract][Full Text] [Related]
14. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.
Jessup CJ; Redston M; Tilton E; Reimann JD
Hum Pathol; 2016 Mar; 49():1-9. PubMed ID: 26826402
[TBL] [Abstract][Full Text] [Related]
15. Muir-Torre syndrome.
Lachiewicz AM; Wilkinson TM; Groben P; Ollila DW; Thomas NE
Am J Clin Dermatol; 2007; 8(5):315-9. PubMed ID: 17902735
[TBL] [Abstract][Full Text] [Related]
16. MSH6, Past and Present and Muir-Torre Syndrome-Connecting the Dots.
Mahalingam M
Am J Dermatopathol; 2017 Apr; 39(4):239-249. PubMed ID: 28323777
[TBL] [Abstract][Full Text] [Related]
17. Lynch Syndrome and Muir-Torre Syndrome: An update and review on the genetics, epidemiology, and management of two related disorders.
Le S; Ansari U; Mumtaz A; Malik K; Patel P; Doyle A; Khachemoune A
Dermatol Online J; 2017 Nov; 23(11):. PubMed ID: 29447627
[TBL] [Abstract][Full Text] [Related]
18. "Second hit" in sebaceous tumors from Muir-Torre patients with germline mutations in MSH2: allele loss is not the preferred mode of inactivation.
Kruse R; Rütten A; Hosseiny-Malayeri HR; Bisceglia M; Friedl W; Propping P; Ruzicka T; Mangold E
J Invest Dermatol; 2001 Mar; 116(3):463-5. PubMed ID: 11231323
[TBL] [Abstract][Full Text] [Related]
19. Papillary Renal Cell Carcinoma in Lynch/Muir-Torre Syndrome with Germline Pathogenic Variant in
Yang Y; Dhar S; Taylor J; Krishnan B
J Kidney Cancer VHL; 2021; 8(2):8-19. PubMed ID: 33977078
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
